全基因组多基因风险评分预测胶质瘤风险及分子亚型
PRS-CS总体预测效能优于PRS-CT,胶质母细胞瘤中每标准差OR为1.93(P=2.0×10-54),PRS-CS第80百分位个体60岁时GBM风险为0.107%(平均PRS者为0.046%,P=2.4×10-12),第95百分位者胶质瘤终生绝对风险达1.18%。
要点
- PRS-CS较PRS-CT在胶质瘤各亚型中解释方差中位提升24%(四分位距11-30%)。
- 胶质母细胞瘤中PRS-CS每标准差OR=1.93(P=2.0×10-54),PRS-CT为OR=1.83(P=9.4×10-50)。
- PRS-CS第95百分位个体胶质瘤终生绝对风险为1.18%,IDH野生型肿瘤为0.76%。
核心结论
- 全基因组PRS有潜力增强高危个体识别并帮助区分预后相关的胶质瘤亚型。
研究设计与样本
- PRS模型使用按组织学分层(10346例病例和14687例对照)和按分子亚型分层(2632例病例和2445例对照)的GWAS训练,并在2个独立队列中验证。
主要发现
- PRS-CS总体较PRS-CT更具预测性,在胶质瘤各亚型中解释方差(R2)中位提升24%(四分位距=11-30%)。
- 胶质母细胞瘤中PRS-CS每标准差OR=1.93(P=2.0×10-54),PRS-CT为OR=1.83(P=9.4×10-50);解释方差R2=2.82% vs R2=2.56%。
- PRS-CS分布第80百分位个体60岁时胶质母细胞瘤风险为0.107%,高于平均PRS者的0.046%(P=2.4×10-12)。
- PRS第95百分位个体胶质瘤终生绝对风险达1.18%,IDH野生型肿瘤为0.76%。
- 在人口学因素基础上加入PRS-CS改善了病例中IDH突变状态的分类(AUC=0.839 vs AUC=0.895,PΔAUC=6.8×10-9)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Polygenic risk scores (PRS) aggregate the contribution of many risk variants to provide a personalized genetic susceptibility profile. Since sample sizes of glioma genome-wide association studies (GWAS) remain modest, there is a need to efficiently capture genetic risk using available data. METHODS: We applied a method based on continuous shrinkage priors (PRS-CS) to model the joint effects of over 1 million common variants on disease risk and compared this to an approach (PRS-CT) that only selects a limited set of independent variants that reach genome-wide significance (P < 5 × 10-8). PRS models were trained using GWAS stratified by histological (10 346 cases and 14 687 controls) and molecular subtype (2632 cases and 2445 controls), and validated in 2 independent cohorts. RESULTS: PRS-CS was generally more predictive than PRS-CT with a median increase in explained variance (R2) of 24% (interquartile range = 11-30%) across glioma subtypes. Improvements were pronounced for glioblastoma (GBM), with PRS-CS yielding larger odds ratios (OR) per standard deviation (SD) (OR = 1.93, P = 2.0 × 10-54 vs. OR = 1.83, P = 9.4 × 10-50) and higher explained variance (R2 = 2.82% vs. R2 = 2.56%). Individuals in the 80th percentile of the PRS-CS distribution had a significantly higher risk of GBM (0.107%) at age 60 compared to those with average PRS (0.046%, P = 2.4 × 10-12). Lifetime absolute risk reached 1.18% for glioma and 0.76% for IDH wildtype tumors for individuals in the 95th PRS percentile. PRS-CS augmented the classification of IDH mutation status in cases when added to demographic factors (AUC = 0.839 vs. AUC = 0.895, PΔAUC = 6.8 × 10-9). CONCLUSIONS: Genome-wide PRS has the potential to enhance the detection of high-risk individuals and help distinguish between prognostic glioma subtypes.
引用
- Nakase T, Guerra GA, Ostrom QT, et al. Genome-wide polygenic risk scores predict risk of glioma and molecular subtypes. Neuro Oncol. 2024. PMID: 38916140. doi:10.1093/neuonc/noae112
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。